TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Details

Ressource 1Download: fimmu-08-01203.pdf (1235.68 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_5787FD5D2175
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.
Journal
Frontiers in immunology
Author(s)
Kaufmann SHE, Dockrell H.M., Drager N., Ho M.M., McShane H., Neyrolles O., Ottenhoff THM, Patel B., Roordink D., Spertini F., Stenger S., Thole J., Verreck FAW, Williams A.
Working group(s)
TBVAC2020 Consortium
Contributor(s)
Britton W., Triccas J., Counoupas C., Grooten J., Demoitie M.A., Romano M., Mascart F., Andersen P., Aagaard C., Christensen D., Ruhwald M., Lindenstrom T., Neyrolles O., Charneau P., Guilhot C., Peixoto A., Gilleron M., Locht C., Brosch R., Inchauspe G., Long SLT, Kaufmann S., Weiner J., Maertzdorf J., Neuwenhuizen N., Bastian M., Stenger S., Caccamo N., Goletti D., Nisini R., Shin S.J., Lee H., Sigal A., Scriba T., Walzl G., Loxton A., Wilkinson R., Cardona P.J., Vilaplana C., Martin C., Marinova D., Aguilo N., Spertini F., Aebersold R., Caron E., Pinschewer D., De Libero G., Siegrist C.A., Collin N., Barnier-Quer C., Sander P., Verreck F., Ottenhoff T., Joosten S., van Meijgaarden K., Coppola M., Geluk A., Drager N., Roordink D., Thole J., Perrie Y., Baird M., Levin M., Dockrell H., Smith S., Fletcher H., Bancroft G., Rawkins A., Clark S., Ho M.M., McShane H., Satti I., Stylianou E., Vordermeier M., Hogarth P.
ISSN
1664-3224 (Print)
ISSN-L
1664-3224
Publication state
Published
Issued date
2017
Peer-reviewed
Oui
Volume
8
Pages
1203
Language
english
Abstract
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Keywords
bacille Calmette–Guérin, biomarker, clinical trial, discovery, portfolio management, tuberculosis, vaccination
Pubmed
Web of science
Open Access
Yes
Create date
14/12/2017 15:19
Last modification date
20/08/2019 14:11
Usage data